Pharmacodynamic response to HER2/CD3 bispecific antibody (HER2-TDB): evidence of T-cell recruitment and further rationale for combination treatment with anti-PD-L1

被引：0
|
作者：
Li, Ji
Hristopoulos, Maria
Clark, Robyn
Johnston, Jennifer
Slaga, Dion
Wang, Bu-Er
Cubas, Rafael
Totpal, Klara
Junttila, Melissa R.
Junttila, Teemu T.
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-1486
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1486
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Phase II clinical trial using anti-CD3 x anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) for HER2-negative (0-2+) metastatic breast cancer.
    Lum, Lawrence G.
    Thakur, Archana
    Al-Kadhimi, Zaid S.
    Deol, Abhinav
    Simon, Michael S.
    Schalk, Dana
    Liu, Qin
    Flaherty, Lawrence E.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [32] Bispecific Antibody PD-L1 x CD3 Boosts the Anti-Tumor Potency of the Expanded Vγ2Vδ2 T Cells
    Yang, Rui
    Shen, Susu
    Gong, Cheng
    Wang, Xin
    Luo, Fang
    Luo, Fengyan
    Yang Lei
    Wang, Zili
    Xu, Shasha
    Ni, Qian
    Xue, Yan
    Fu, Zhen
    Zeng, Liang
    Fang, Lijuan
    Yan, Yongxiang
    Zhang, Jing
    Gan, Lu
    Yi, Jizu
    Zhou, Pengfei
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [33] A B7-H3-Targeted CD28 Bispecific Antibody Enhances the Activity of Anti-PD-1 and CD3 T-cell Engager Immunotherapies
    Moore, Gregory L.
    Zeng, Veronica G.
    Diaz, Juan E.
    Bonzon, Christine
    Avery, Kendra N.
    Rashid, Rumana
    Qi, Jing
    Nam, Dong Hyun
    Jacinto, Jonathan
    Dragovich, Matthew A.
    Kim, Yoon Kyung
    Balcazar, Karen P.
    Bakhit, Charles G.
    Eivazi, Araz
    Nguyen, Hanh
    Muchhal, Umesh S.
    Szymkowski, David E.
    Desjarlais, John R.
    Hedvat, Michael
    MOLECULAR CANCER THERAPEUTICS, 2025, 24 (03) : 331 - 344
  • [34] Anti-PD-1/Her2 Bispecific Antibody IBI315 Enhances the Treatment Effect of Her2-Positive Gastric Cancer through Gasdermin B-Cleavage Induced Pyroptosis
    Lin, Wu
    Zhang, Yingzi
    Yang, Yan
    Lin, Ben
    Zhu, Mengjia
    Xu, Jinling
    Chen, YiRan
    Wu, Weiwei
    Chen, Bingliang
    Chen, Xiangliu
    Liu, Jin
    Wang, Haohao
    Teng, Fei
    Yu, Xiongfei
    Wang, Haiyong
    Lu, Jun
    Zhou, Quan
    Teng, Lisong
    ADVANCED SCIENCE, 2023, 10 (30)
  • [35] A Novel Her2/VEGFR2/CD3 trispecific antibody with an optimal structural design showed improved T-cell-redirecting antitumor efficacy
    Liu, Dong
    Qi, Xuexiu
    Wei, Xiaoyi
    Zhao, Lijun
    Wang, Xuechun
    Li, Shuhong
    Wang, Zhidong
    Shi, Licai
    Xu, Jiean
    Hong, Mei
    Liu, Zhong
    Zhao, Lili
    Wang, Xiankun
    Zhang, Bo
    Zhang, Yuhan
    Wang, Feng
    Cao, Yu J.
    THERANOSTICS, 2022, 12 (18): : 7788 - 7803
  • [36] Anti-PD-L1 x anti-CD3 bispecific T-cell engager-armed T cells can overcome immunosuppression and redirect T cells to kill breast cancer cells expressing PD-L1
    Luangwattananun, Piriya
    Sangsuwannukul, Thanich
    Supimon, Kamonlapat
    Thuwajit, Chanitra
    Chieochansin, Thaweesak
    Sa-nguanraksa, Doonyapat
    Samarnthai, Norasate
    O-Charoenrat, Pornchai
    Junking, Mutita
    Yenchitsomanus, Pa-thai
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 124
  • [37] Tumor-Localized Costimulatory T-Cell Engagement by the 4-1BB/HER2 Bispecific Antibody-Anticalin Fusion PRS-343
    Hinner, Marlon J.
    Aiba, Rachida Siham Bel
    Jaquin, Thomas J.
    Berger, Sven
    Duerr, Manuela Carola
    Schlosser, Corinna
    Allersdorfer, Andrea
    Wiedenmann, Alexander
    Matschiner, Gabriele
    Schueler, Julia
    Moebius, Ulrich
    Rothe, Christine
    Matis, Louis
    Olwill, Shane Anthony
    CLINICAL CANCER RESEARCH, 2019, 25 (19) : 5878 - 5889
  • [38] Correction: Preclinical In Vivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T‑Cell Bispecific in Combination with Anti‑PD‑L1
    Javier Sánchez
    Valeria Nicolini
    Linda Fahrni
    Inja Waldhauer
    Antje‑Christine Walz
    Candice Jamois
    Stephen Fowler
    Silke Simon
    Christian Klein
    Pablo Umaña
    Lena E. Friberg
    Nicolas Frances
    The AAPS Journal, 25
  • [39] AVAIL-T: A Phase 2a Trial of Avelumab, and Anti-PD-L1 Antibody, in Relapsed and Refractory Peripheral T-Cell Lymphoma (PTCL)
    Ahearne, Matthew J.
    Gaskell, Charlotte
    Jackson, Aimee E.
    Morland, Clare
    Hopkins, Louise
    Nawaz, Nadia
    Timmins, Matthew A.
    Fox, Christopher P.
    Collins, Graham P.
    Davies, Andrew
    Lewis, David John
    Cwynarski, Kate
    Linton, Kim
    Mckay, Pam
    Johnson, Rod
    Wagner, Simon D.
    BLOOD, 2020, 136
  • [40] Combination of AMG 160, a PSMA x CD3 half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, with an anti-PD-1 antibody in prostate cancer (PCa)
    Paweletz, Katherine L.
    Li, Shyun
    Bailis, Julie M.
    Juan, Gloria
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345